irvine, california, June 12, 2023 /PRNewswire/ — AIVITA Biomedical, Inc., a biotechnology company specializing in innovative stem cell applications, today announced that its Chairman and CEO, Dr. Hans Keilstedt Keynote speech at upcoming Digital Innovation Summit June 12-13 of St Andrews, New Brunswick,Canada.
Hosted by University of New Brunswick McKenna Institute, 2nd Annual Digital Innovation Summit Brings Global Experts, Technology Leaders and Changemakers to Define and Accelerate new brunswick Digital future. The conference is expected to accelerate action, innovation and growth in the technology sector.
Dr. Kiested will deliver one of two keynotes on the 12th, the other Tessa Lion, Director of Product Management at Instagram. The keynote will be delivered in the evening session entitled “How to Create Movements for Change.” In his keynote, Dr. Kiested will discuss the potential of AI to transform healthcare and the power of data trust.
“AI is already transforming everything from patient management to drug discovery in healthcare,” said Dr. Kirstedt. “I look forward to sharing my insights and predictions with this amazing group.”
About Aivita Biomedical
Founded in 2016 by pioneers in the cell therapy industry, AIVITA Biomedical, Inc. leverages its expertise in stem cell expansion and directed high-purity differentiation to develop safe, efficient, and efficient biomedical solutions that support the therapeutic pipeline. Realize an economical manufacturing system. Our immuno-oncology therapies target tumor-initiating cells of all cancer types with a unique pan-antigen approach that targets all neoantigens unique to a patient’s cancer. Our patient-specific cancer therapies show great promise, including eradicating tumors without adverse side effects in melanoma and renal cell carcinoma, and extending progression-free survival in glioblastoma is shown. Our 2019-nCoV vaccine enablement kits are targeted at emerging markets and enable point-of-care vaccine production in facilities with minimal equipment by minimally trained third-party technicians.
Cautionary Note Regarding Forward-Looking Statements
This notice contains statements, where applicable, that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations, assumptions and other statements that are not necessarily historical facts. Please note that these forward-looking statements are only predictions and are subject to risks and uncertainties. In addition, forward-looking statements speak only as of the date they are made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data relevant to our business and industry, including some market data that we believe to be reasonable as of the date of this communication and most material to our forecasts. Includes forecasts based on assumptions. If any of our assumptions prove incorrect, our actual results could differ materially from our projections based on those assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any securities described herein.
Source AIVITA Biomedical, Inc.
